Page last updated: 2024-12-05

hydratropic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hydratropic acid, also known as 2-phenylpropionic acid, is a chiral organic compound with the formula C9H10O2. It is a colorless liquid with a pungent odor. It is found naturally in some plants and is also a precursor to several important pharmaceuticals. The compound has been studied for its potential applications in various fields, including medicine, agriculture, and materials science. Hydratropic acid has shown activity as an anti-inflammatory, analgesic, and antipyretic agent. It is also being investigated as a potential treatment for Alzheimer's disease. The synthesis of hydratropic acid is achieved through various methods, including the Friedel-Crafts acylation of benzene with propionic acid, followed by reduction. Its importance lies in its potential to act as a building block for the synthesis of various complex molecules with pharmacological properties. The study of hydratropic acid is driven by its potential to provide a valuable lead compound for the development of new drugs and materials.'

hydratropic acid: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

hydratropic acid : A 2-arylpropionic acid carrying a phenyl group at position 2. It is a metabolite of alpha-methylstyrene (AMS), a volatile hydrocarbon. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10296
CHEMBL ID370925
CHEBI ID48526
SCHEMBL ID3418
MeSH IDM0060455

Synonyms (94)

Synonym
benzeneacetic acid, .alpha.-methyl-, (s)-
benzeneacetic acid, .alpha.-methyl-, (r)-
2-phenylpropionic acid
492-37-5
.alpha.-phenylpropionic acid
hydratropic acid
.alpha.-methylphenylacetic acid
nsc42872
2-phenylpropanoic acid
nsc-42872
benzeneacetic acid, .alpha.-methyl-
.alpha.-methylbenzeneacetic acid
nsc-245032
nsc245032
nsc-245033
nsc245033
2328-24-7
alpha-phenylpropioic acid
2-phenylpropionic acid, 97%
alpha-methylphenylacetic acid
alpha-phenylpropionic acid
CHEBI:48526 ,
alpha-methylbenzeneacetic acid
(+-)-hydratropasaeure
(+-)-hydratropic acid
hydratropasaeure
AC-3206
ypgcwemnnlxisk-uhfffaoysa-
inchi=1/c9h10o2/c1-7(9(10)11)8-5-3-2-4-6-8/h2-7h,1h3,(h,10,11)
dl-2-phenylpropionic acid
CHEMBL370925
2-phenyl-propionic acid
(r)-(-)-hydratropic acid
P0699
A9828
(s)-2-phenyl-propionicacid
AKOS005206767
(+/-)-hydratropic acid
STL164373
nsc 42872
einecs 207-752-0
benzeneacetic acid, alpha-methyl-
ch15e393a2 ,
nsc 245033
unii-ch15e393a2
FT-0625395
FT-0601502
FT-0601503
PS-4663
AM20040558
(+/-)-2-phenylpropionic acid
S6321
SCHEMBL3418
dl-ppa
alpha-phenyl propionic acid
(+/-) 2-phenylpropionic acid
(+/-)2-phenylpropionic acid
racemic (+)-alpha-methyl-alpha-phenylacetic acid
(rs)-2-phenylpropionic acid
2-phenyl propionic acid
racemic 2-phenylpropionic acid
(rac.)-2-phenylpropionic acid
2-phenyl propanoic acid
SY020842
mfcd00063140
mfcd00063139
SY021075
dl-.alpha.-phenylpropionic acid
propanoic acid, 2-phenyl
W-106031
2-phenylpropionicacid
STR03808
mfcd00002650
(?)-2-phenylpropionic acid
F0001-1284
(+/-)-2-phenylpropanoic acid
2-phenylpropionic acid [mesh: hydratropic acid]
alpha-phenylpropioate
hydratropic acid [mesh: hydratropic acid]
HY-W015608
SY004963
CS-W016324
BCP16764
DTXSID80862027
Q27121253
BCP14307
r-1-benzylglycerol
sodium4-pyridinecarboxylatetetrahydrate
dl-?-phenylpropionic acid
a-methylbenzeneacetic acid
F13477
EN300-69310
Z756118128
PD099465

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The results showed that under standard light-dark cycle pharmacokinetic parameters of T1/2 alpha and CL are stereoselective and under reverse light-dark cycle, parameters T1/2 beta, AUC, CL, Vc and MRT were shown to be stereoselective."( [The stereoselectivity of chrono-pharmacokinetic parameters of hydratropic acid in rats].
He, SX; He, YS; Lu, HL; Wang, DY, 1993
)
0.53
"The circadian rhythms of hydratropic acid (HTA) pharmacokinetic parameters were studied by using consinor method."( [Stereoselective chronopharmacokinetics of hydratropic acid in rats].
He, SX; He, YS; Lu, HL; Wang, DY, 1993
)
0.85

Dosage Studied

ExcerptRelevanceReference
" In NEBL-rats, the decrease of (R)-(-)-enantiomer percentage of HTA in plasma was only 2% in 55 min, but the (R)-(-)-enantiomer percentages of HTA acyl glucuronide (HTA-G) in plasma and liver at 1 hr after dosing were 40% and 30%, respectively."( Stereoselective metabolism of 2-phenylpropionic acid in rat. II. Studies on the organs responsible for the optical isomerization of 2-phenylpropionic acid in rat in vivo.
Nakamura, Y; Yamaguchi, T,
)
0.13
" Further studies established the dose-response relationships for these biochemical changes."( Lack of stereoselectivity of the peroxisome proliferation induced by 2-phenylpropionic acid: evidence against a role for lipid disturbance in peroxisome proliferation.
Ahmad, D; Caldwell, J, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-arylpropionic acidA class of carboxylic acids of general formula RCHCH3C(=O)OH where R represents an aryl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)1,230.27000.00020.59827.0000AID509464
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID509464Inhibition of human recombinant FAAH2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Chemistry around imidazopyrazine and ibuprofen: discovery of novel fatty acid amide hydrolase (FAAH) inhibitors.
AID251807Inhibition of CXCL8-induced chemotaxis of human polymorphonuclear cells at 10e-8 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (29.73)18.7374
1990's9 (24.32)18.2507
2000's10 (27.03)29.6817
2010's6 (16.22)24.3611
2020's1 (2.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.16 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (97.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]